What are the precautions for enasidenib?

Ensidipine is an isocitrate dehydrogenase2 inhibitor indicated for the treatment of isocitrate dehydrogenase2 detected in an FDA-approved test. (IDH2)Adult patients with relapsed or refractory acute myeloid leukemia(AML). What are the precautions for enasidenib?

1.In clinical trials, 14%of patients treated with IDHIFA developed differentiation syndrome, which may be life-threatening or fatal if left untreated. Differentiation syndrome is associated with rapid proliferation and differentiation of myeloid cells. Although there are no diagnostic tests to identify the syndrome, symptoms in patients treated with IDHIFA included acute respiratory distress manifesting as dyspnea or hypoxia (68%) and Requires supplemental oxygen(76%); pulmonary infiltrates(73%)and pleural effusion(45%); Renal impairment(70%); Fever(36%); Lymphadenopathy(33%); Bone pain< /span>(27%); peripheral edema with rapid weight gain(21%); and pericardial effusion(18%). Hepatic, renal, and multi-organ dysfunction was also observed. A differentiation syndrome with or without hyperleukocytosis was observed between 1 days and 5 months after initiation of IDHIFA. If differentiation syndrome is suspected, initiate oral or intravenous corticosteroids (eg, 10 mg of dexamethasone every 12 hours) and monitor hemodynamics until symptoms improve. Taper corticosteroids only after symptoms resolve. Premature discontinuation of corticosteroid therapy may result in recurrence of differentiation syndrome symptoms. If severe pulmonary symptoms or renal insufficiency requiring intubation or ventilator support persist more than 48 hours after initiation of corticosteroids, interrupt IDHIFA until signs and symptoms are no longer severe. It is recommended to be hospitalized for close observation and monitoring of patients with pulmonary disease and/Or patients with renal manifestations.

2.Embryo-Fetal toxicity. Based on animal embryo-fetal toxicity studies, IDHIFA can cause embryonic-fetal damage when administered to pregnant women. In animal embryo-fetotoxicity studies, the area under the concentration-time curve(AUC) at the recommended human dose ), Ensidipineinduced embryo-fetal toxicity starting at 0.1 times the steady-state clinical exposure. Inform pregnant women of potential risks to the fetus. Advise females of reproductive potential to use effective contraception during treatment with IDHIFA and for at least 2 months after the last dose. Advise men who are partners of a female of reproductive potential to use effective contraception during treatment with IDHIFA and for at least 2 months after the last dose.

3.Safety and effectiveness in pediatric patients have not been established.

4.Medication for the elderly. Ensidipine does not require dose adjustment based on age. In clinical studies, 61% of 214 patients were 65 years or older, and 24% were 75 years or older. No overall differences in efficacy or safety were observed between patients 65 years of age or older and younger patients.

5.Ensidipine is an OATP1B1, OATP1B3 and BCRP inhibitor. Coadministration with IDHIFA increases exposure to OATP1B1, OATP1B3, and BCRP substrates, which may increase the incidence and severity of adverse reactions with these substrates. Reduce the dose of OATP1B1, OATP1B3, and BCRP substrates as recommended and clinically indicated in the corresponding prescribing information. If you want to get more quality information, you can contact usYaoDe, YaoDe will do its best to learn more about overseas high-quality drugs for you.